38 results about "Visceral adipose" patented technology

A medical image diagnosing support apparatus comprises: a first extraction means which extracts a body region of a subject from a tomographic image of the subject acquired by a medical tomographic apparatus; a second extraction means which extracts a non-adipose region from the body region; a third extraction means which extracts a total body adipose region from the body region; a separation means which separates the total body adipose region into a visceral adipose region and a subcutaneous adipose region based on positional information of the non-adipose region; and a display control means which controls of displaying the tomographic image on an image display device with clear indication of the visceral adipose region and the subcutaneous adipose region.

The present invention provides polypeptides which are predominately expressed in visceral adipose tissue which can be used as markers for the measurement of the levels of visceral adipose tissue in a subject. The invention also provides methods for the measurement of the levels of visceral adipose tissue by obtaining a biological sample and detecting and / or measuring the increase of one or more polypeptides as disclosed herein. Screening methods relating to agonists and antagonists of the specific polypeptides disclosed herein are provided. Antibodies may also be raised against these polypeptide markers for the detection and / or treatment of metabolic syndrome related comorbidities.

The invention discloses a strain of Bifidobacterium longum MF-269 and application thereof. The Bifidobacterium longum MF-269 is preserved in China General Microbiological Culture Collection Center on January 4, 2021, and the preservation number of the Bifidobacterium longum MF-269 is CGMCC (China General Microbiological Culture Collection Center) No: 21587. The Bifidobacterium longum MF-269 is separated and identified from human excrement for the first time, and research finds that the Bifidobacterium longum MF-269 can remarkably reduce fat cells and reduce the weight of visceral fat, so the effect of reducing the body weight of a mouse is effectively achieved, the content of cholesterol, triglyceride and low-density lipoprotein of the mouse can be reduced, and the liver function is improved; the strain is sourced from healthy human bodies, can produce small molecular acid, has choline salt hydrolase activity and antibiotic resistance, is free of toxic and antigen reaction, can be used as probiotics to prepare multifunctional medicines, functional foods or health foods, and has wide market prospects and application values.

The invention relates to an siRNA for inhibiting expression of an FABP4 gene. A sequence of the siRNA is shown as follows: sense strand: 5'-CGACCACAAUAAAGAGAAA-3' antisense strand: 5'-UUUCUCUUUAUUGUGGUCG-3'. According to the siRNA disclosed by the invention, three pairs of siRNA sequences are designed, aiming at the FABP4 gene, and an siRNA which is capable of effectively down regulating expression of a target gene is screened by virtue of a cell transfection test; according to the screened siRNA-368 sequence, a corresponding lentivirus expression carrier is constructed; and verified by a test of transfecting an obese mouse with high fat and inhibiting expression of mouse visceral fat tissue FABP4 gene, the screened siRNA is capable of effectively inhibiting expression of the mouse FABP4 gene and lowering weight, glycosylated hemoglobin, total cholesterol and level of low-density lipoprotein cholesterol of the obese mouse with high fat.

The invention provides an automatic intra-abdominal muscle and fat image segmentation method, which is used for simultaneously segmenting abdominal muscle tissues, visceral fat tissues and subcutaneous fat tissues. The method mainly comprises the following steps of: classifying pixels of an abdominal image to obtain a preliminary pixel value change range of fat tissues, muscle tissues and a background part; Secondly, performing further segmentation on the basis of the pixel value change range of the muscle tissue to obtain an outer contour part and an inner contour part of the muscle respectively, and finishing the segmentation of the muscle tissue based on the parts. Finally, the adipose tissue segmented in the first step is divided into two parts by the muscle tissue, and the visceral adipose tissue is located in the muscle tissue. The subcutaneous adipose tissue is located outside the muscle tissue. Compared with the prior art, the method has the advantages that all sliced musculartissues and adipose tissues are segmented at a time, the correct rate is high, and full-automatic segmentation is achieved.

The invention relates to an intra-abdominal adipose tissue segmentation method based on deep learning, and is used for segmenting visceral adipose tissue and subcutaneus adipose tissue at the same time. The method comprises the following steps: recognizing abdominal adipose tissue pixel points; performing deep learning on the recognized abdominal adipose tissue pixel points, so as to obtain substantive characteristics of the abdominal adipose tissue pixel points; inputting the substantive characteristics of the abdominal adipose tissue pixel points into a classification algorithm, so as to obtain a preliminary segmentation result; converting the preliminary segmentation result to a polar coordinate, and further amending abdominal adipose tissue pixel points which are misclassified, so as to obtain an abdominal adipose tissue segmentation map; computing the ratios of various adipose tissues in the abdominal adipose tissue segmentation map according to gradients, and visually displaying a computed result through a volume rendering technology. Compared with the prior art, the method has the advantages that the application is timely, retraining is not required, the error rate is low, the precision degree is high, and fully automatic segmentation is realized.

The invention relates to a method for separating, purifying and identifying intramuscular fat cells of Qinchuan beef cattle. The method comprises the following steps: digesting longissimus dorsi of the Qinchuan beef cattle with type II collagenase, neutralizing tissue blocks digested by the type II collagenase by using a DMEM / F12 medium containing 10% of fetal bovine serum, filtering and centrifuging to obtain cells; washing and centrifuging the cells, re-suspending the cells in the DMEM / F12 medium containing 10% of FBS (Fetal Bovine Serum), counting, inoculating the cells in a culture dish, culturing in a CO2 incubator for 1.5 hours, and washing to remove non-adherent cells with a sterile phosphate buffer solution; culturing the cells in an incubator having a CO2 concentration of 5% at 37DEG C, changing the medium once every 2 days, and performing cellular immunofluorescence labeled positive cell identification after the cell confluence degree reaches 70-80%. The intramuscular fat cells of the beef cattle obtained by the method in the invention have high a preadipocyte positive rate, and a foundation is laid for study of not increasing subcutaneous and visceral fat deposition while improving intramuscular fat deposition.

A method and system for determining normalized metrics for visceral adipose tissue (VAT) mass and volume estimation. The normalized metrics including a VAT average cross-section determined by dividing a VAT volume by a height of the abdominal region of interest, and a VAT linear mass density determined by dividing the VAT mass by a height of an abdominal region of interest.

The invention relates to the field of artificial intelligence, and provides an image segmentation method, which comprises the steps of converting abdominal CT image data in a DICOM format into an abdominal image in a JPG format; inputting the abdomen image in the JPG format into a generative network model constructed based on a Vnet network model; generating a 6-channel prediction segmentation label through the generation network model; and obtaining a prediction segmentation result image according to the 6-channel prediction segmentation label, the prediction segmentation result image comprising a subcutaneous fat image, a muscle image, a bone image, a visceral fat image, a visceral organ image and a background image. In addition, the invention further relates to a blockchain technology,and the abdomen CT image data in the DICOM format and the abdomen image in the JPG format are stored in a blockchain. Therefore, the segmentation effect of the abdominal muscle image and the fat imagecan be improved.

The invention discloses a green tea and carnitine capsule with the function of reducing weight. The green tea and carnitine capsule is characterized by being prepared in the following steps of taking a green tea extract with green tea as the raw material, adding L-carnitine tartrate, carrying out mixing, granulating, drying and straightening, then adding silicon dioxide and magnesium stearate, mixing the materials uniformly, then filling the mixture in a capsule and carrying out polishing, packaging and irradiation sterilization, thus preparing the green tea and carnitine capsule. The green tea and carnitine capsule has the beneficial effects that the green tea and carnitine capsule takes green tea and L-carnitine tartrate as the raw materials and organically combines the theory of traditional Chinese medicine with modern medicine to achieve the functions of removing fat and reducing weight; the traditional high-temperature green tea extraction method is changed, thus retaining the natural substances of fresh leaves; green tea hydrolysate obtained by adopting enzyme extraction is easy in control of molecular weight, has greenness and has strong activity and important biological functions, thus achieving the function of inhibiting obesity, especially visceral fat.

The present invention relates to human milk fortifiers comprising high protein content and long chain poly-unsaturated fatty acids. Use of such human milk fortifier improves the body adipose tissue distribution by increasing the subcutaneous adipose tissue mass, while at the same time not increasing visceral adipose tissue.

The invention discloses application of an HIF2alpha agonist and an ACER2 agonist in preparation of a medicine for treating and / or preventing atherosclerosis. Wherein the HIF2alpha agonist can be an adipose cell HIF2alpha agonist, and the ACER2 agonist can be a visceral fat ACER2 enzyme activator. The invention also discloses an application of Roxadustat in preparing a medicine for treating and / orpreventing atherosclerosis. The HIF2alpha agonist, the ACER2 agonist and the Roxadustat can be used for inhibiting or alleviating the occurrence and development of atherosclerosis.

A method and system for estimating the visceral adipose tissue (VAT) mass or volume of a subject comprises performing a dual-energy X-ray scan of the subject; generating at least one image of the subject from the dual-energy X-ray scan; identifying a region of interest on the at least one image; dividing the region of interest into a plurality of sections; determining an outer transverse extent of a coelom or inner abdominal cavity of the subject; determining a subcutaneous adipose tissue (SAT) composition for each of the plurality of sections, wherein the SAT composition determination is restricted to an area directly anterior and posterior the coelom or inner abdominal cavity of the subject; and determining a VAT mass and / or volume for the region of interest based on the determined SAT composition for each of the plurality of section.

The invention relates to the technical field of health care food and especially relates to a traditional Chinese medicine composition, a preparation method and application thereof. The traditional Chinese medicine composition is prepared from coix seeds, sea buckthorn fruits, exocarpium citri rubrum and licorice roots. Through adopting relatively few kinds of medicines with a reasonable proportioning, the traditional Chinese medicine composition has remarkable effects of reducing lumbo-abdominal circumference, reducing visceral adipose and resisting inflammation and has no side effect.

The invention relates to nutritional compositions comprising specifically designed lipid globules that are especially suited for preterm infants, small for gestational age infants and infants with retarded growth due to physical or mental stress after birth, for promoting catch-up growth and / or for use in improving body composition, improving adipose tissue distribution, decreasing visceral adipose tissue based on body weight and / or on total adipose tissue, and / or decreasing the ratio visceral adipose tissue to subcutaneous adipose tissue, in such infants, and / or providing nutrition to such infants.

A method and system for estimating the visceral adipose tissue (VAT) of a subject comprising performing a dual-energy X-ray scan of the subject; generating at least one image of the subject from the dual-energy X-ray scan; identifying a region of interest; dividing the region of interest into a plurality of sections; generating a soft tissue composition profile for each of the plurality of sections, wherein the soft tissue composition profile identifies an edge of the subject, an outer edge of an abdominal wall of the subject, a subcutaneous region and a subcutaneous thickness for each of the plurality of sections; determining a subcutaneous adipose tissue (SAT) composition for each of the plurality of sections, wherein a subcutaneous fat fraction is used to calculate the subcutaneous fat and lean masses and / or volumes; and determining a VAT based on the determined SAT composition for each of the plurality of sections.

The invention discloses a visceral fat measuring device based on patient health, the visceral fat measuring device comprises a visceral fat measuring instrument body, the visceral fat measuring instrument body is provided with a foot standing part and a hand holding part, the foot standing part is slidably connected with a support member for supporting the leg of any side of a patient with leg disability, and the hand holding part is slidably connected with the support member. According to the visceral fat measuring device based on the health of the patient, by means of the arranged supporting piece, when visceral fat of the disabled is measured, the legs of the disabled cannot make contact with the contact face for normal measurement, and the visceral fat measuring device is more convenient to use. The defect that the patient with the disabled legs cannot stand normally during standing is overcome, the operation process that the patient with the disabled legs cannot conduct normal detection is overcome, adjustment can be conducted through the supporting piece according to the length of the residual limbs of the patient, the supporting piece plays a supporting role on the patient, and therefore normal detection of the patient is guaranteed.

Provided is a metabolism improving agent that comprises an alkalizer such as an acidosis ameliorating agent or a urine alkalizer as an active ingredient and has effects of improving insulin resistance, improving pituitary and adrenal functions, reducing visceral fat accumulation, etc.

The invention belongs to the technical field of medicine preparation, and in particular relates to the application of adipokines GREM2 in the preparation of medicines for treating obesity. By detecting the serum GREM2 level, it was found that the serum GREM2 level of obese patients was significantly higher than that of normal weight controls. Through expression profiling analysis, it was found that the secreted factor GREM2 was mainly expressed in visceral adipose tissue. Further in vitro primary adipocyte induction experiments found that overexpression of GREM2 can significantly inhibit the ability of adipocytes to differentiate into beige fat, inhibit the function of mitochondria, and significantly reduce the expression of brown fat-specific gene UCP1. This effect is mediated by inhibiting the BMP / Smad signaling pathway. The present invention finds for the first time that the secretion factor GREM2 is mainly derived from mature white fat cells, and that GREM2 is involved in the browning process of white fat. Therefore, GREM2 can provide a new drug target for the clinical treatment of obesity.

A method and system for estimating the visceral adipose tissue (VAT) mass or volume of a subject comprises performing a dual-energy X-ray scan of the subject; generating at least one image of the subject from the dual-energy X-ray scan; identifying a region of interest on the at least one image; dividing the region of interest into a plurality of sections; determining an outer transverse extent of a coelom or inner abdominal cavity of the subject; determining a subcutaneous adipose tissue (SAT) composition for each of the plurality of sections, wherein the SAT composition determination is restricted to an area directly anterior and posterior the coelom or inner abdominal cavity of the subject; and determining a VAT mass and / or volume for the region of interest based on the determined SAT composition for each of the plurality of section.

The invention relates to a method for judging visceral lipopexia susceptibility. According to the method, the type of SNP represented by dbSNP:IDrs9904288 contained in a DNA sample acquired from a testee is taken as an index to judge the susceptibility of genetic predisposition of visceral lipopexia, dangerousness of increase of visceral fat, dangerousness of attack or development of disease or state caused by visceral lipopexia of the testee.

A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome.

The present invention relates to a visceral adipose tissue macrophage-targeted non-viral gene / carrier complex for preventing and treating obesity-induced type II diabetes. More specifically, the gene / carrier complex according to the present invention delivers a therapeutic gene in a stable manner in a case of being injected into the body with the visceral adipose tissue macrophages being targeted, and thus exhibits an excellent inhibitory effect against TACE, which allows the gene / carrier complex to be applied for prevention or treatment of obesity-induced type II diabetes.

Disclosed is an agent for accelerating the increase in and / or preventing the decrease in the blood adiponectin level, or a food, beverage or animal feed for accelerating the increase in and / or preventing the decrease in the blood adiponectin level, which comprises a culture or cell of a lactic acid bacterium belonging to the genus Lactobacillus, particularly Lactobacillus gasseri or Lactobacillus helveticus as an active ingredient. Also disclosed is a visceral fat accumulation inhibitor or a food or beverage for inhibiting the accumulation of a visceral fat, which comprises a culture or cell of Lactobacillus helveticus as an active ingredient.

The invention relates to a medicine for treating burns, scalds and burns. The medicine is mainly prepared from animal viscera fat cells as raw materials and white granulated sugar as an auxiliary material. According to the medicine, on one hand, animal viscera fat cells are used for regenerating and repairing organism tissues and skin tissues, on the other hand, the hyperosmosis characteristic of the white granulated sugar is used for dehydrating and apoptosis of possibly infected and existing bacterial cells on a wound surface, and meanwhile, the air permeability of crystal micropores of the white granulated sugar is used for dissipating organism heat, so that the heat of the organism is dissipated; inflammation and swelling of the body are eliminated, wound pain is relieved, and rapid healing of wounds is promoted. The raw materials used by the medicine are common substances, the preparation process is not complicated, the cost is low, and the effect is good.

The invention discloses a machine learning-based human body weight loss program recommendation method, system and medium, constructs a training set, and collects several measured values ​​of human body functions for each training sample; preprocesses the collected measured values; The features of basal metabolic rate, trunk subcutaneous fat percentage and visceral fat index are extracted from the measured values, and the extracted features of basal metabolic rate, trunk subcutaneous fat percentage and visceral fat index are fused, and the fused features of each sample are combined with each The pre-set weight loss program labels for each sample are input into the pre-built neural network model for training, and the trained neural network model is obtained; a number of human body function measurement values ​​are collected for the test samples; the collected measurement values ​​are preprocessed; Three features are extracted from the preprocessed measurement values, and feature fusion is performed. The fused features of each test sample are input into the trained neural network model, and the recommended weight loss plan is output.